Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12156565 | 0.87 | TACR1 (0.36) | TACR1SMN1; SMN2KDM4EALDH1A1SIGMAR1 | |
| SCHEMBL12156552 | 0.87 | TACR1 (0.36) | TACR1SMN1; SMN2KDM4EALDH1A1SIGMAR1 | |
| SCHEMBL18120978 | 0.86 | PTGS2 (0.36) | SMN1; SMN2ALDH1A1SIGMAR1LMNAPTGS2 | |
| SCHEMBL70778 | 0.78 | TSHR (0.46) | SMN1; SMN2KDM4EALDH1A1LMNA | |
| SCHEMBL12379861 | 0.78 | TSHR (0.46) | SMN1; SMN2KDM4EALDH1A1LMNA | |
| SCHEMBL1133592 | 0.78 | — | — | |
| SCHEMBL18573949 | 0.78 | SIGMAR1 (0.49) | TACR1SMN1; SMN2KDM4EALDH1A1SIGMAR1 | |
| SCHEMBL25981963 | 0.77 | ALDH1A1 (0.39) | TACR1SMN1; SMN2KDM4EALDH1A1SIGMAR1 | |
| SCHEMBL20031882 | 0.76 | TACR1 (0.35) | TACR1SMN1; SMN2KDM4EALDH1A1SIGMAR1 | |
| SCHEMBL17706710 | 0.75 | L3MBTL1 (0.43) | SMN1; SMN2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7226578-B2 | Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis | SHERING AG (DE) | 2007-06-05 | — | — | US | disclosed |
| US-6916461-B2 | Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis | SCHERING AG (DE) | 2005-07-12 | — | — | US | disclosed |
| US-20050147563-A1 | Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-07-07 | — | — | US | disclosed |
| US-20030232012-A1 | Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis | SCHERING AG (DE) | 2003-12-18 | — | — | US | disclosed |
| US-6468502-B1 | PARAMAGNETIC MACROMOLECULES WITH HIGHER PROTON RELAXIVITY; LOWER DOSAGE AND INCREASED SIGNAL INTENSITY; DETECTING VASCULAR DISEASES; DIFFERENTIATING TISSUE BLOOD SUPPLY LEVELS; DISTINGUISHING MYOCARDIAL INFARCTION FROM ISCHEMIA | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-10-22 | — | — | US | disclosed |
| EP-0874645-B1 | PERFLUOROALKYL-CONTAINING METAL COMPLEXES AND THEIR USE IN NMR DIAGNOSTICS | SCHERING AG (DE) | 2002-04-03 | — | — | EP | disclosed |
| EP-0882010-B1 | PHARMACEUTICAL AGENTS CONTAINING PERFLUOROALKYL-CONTAINING METAL COMPLEXES AND THE USE THEREOF IN TUMOUR THERAPY AND INTERVENTIONAL RADIOLOGY | SCHERING AG (DE) | 2001-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050147563-A1 | Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis | FABP1, FLOT1, AFF1 | TACR1 2193/4885SMN1; SMN2 3273/4885KDM4E 4553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.